Literature DB >> 30521744

Pharmacological treatment of obesity

Aldo Ferreira-Hermosillo1, Latife Salame-Khouri, Dalia Cuenca-Abruch.   

Abstract

More than 70% of the population in Mexico is overweight or obese, affecting mainly people in productive age. Obesity is associated with the development of diseases that increase cardiovascular risk (diabetes mellitus, hypertension or atherogenic dyslipidemia), diseases that limit the quality of life of the patient (osteoarthrosis or sleep apnea) and even with the increase in the incidence of certain types of cancer (breast or colon). It is evident that the decrease of at least 5% of body weight induces improvement in all these factors; however, in some patients it is difficult to achieve this goal only with lifestyle modifications. In this review we analyze some drugs approved for weight control by national and international agencies that can serve as an auxiliary in conjunction with diet and exercise. Treatment must be individualized according to each patient characteristics, with an adequate evaluation of their risks and benefits.

Keywords:  Obesity; Anti-Obesity Agents; Adrenergic Agents; Serotonin Agents; Glucagon-Like Peptide 1

Year:  2018        PMID: 30521744

Source DB:  PubMed          Journal:  Rev Med Inst Mex Seguro Soc        ISSN: 0443-5117


  1 in total

1.  Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial.

Authors:  Aldo Ferreira-Hermosillo; Mario Antonio Molina-Ayala; Diana Molina-Guerrero; Ana Pamela Garrido-Mendoza; Claudia Ramírez-Rentería; Victoria Mendoza-Zubieta; Etual Espinosa; Moisés Mercado
Journal:  Trials       Date:  2020-02-14       Impact factor: 2.728

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.